Premium
Successful 2‐week treatment with terbinafine (Lamisil®) for moccasin tinea pedis and tinea manuum
Author(s) -
WHITE J.E.,
PERKINS P.J.,
EVANS E.G.V.
Publication year - 1991
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/j.1365-2133.1991.tb14752.x
Subject(s) - terbinafine , medicine , placebo , mycosis , dermatology , dermatophyte , dermatomycosis , antifungal , itraconazole , surgery , pathology , alternative medicine
Summary A new orally active antifungal agent, terbinafine, was used in the treatment of tinea pedis (‘dry type’ or moccasin type) and tinea manuum. Fifty‐three adults over the age of 16 years with fungal infections of the feet and/or hands were treated with either oral terbinafine, 250 mg, or placebo, once daily for 2 weeks. The diagnosis of fungal infection was confirmed by examination of skin scrapings by microscopy and culture. Of these, 28 patients were evaluable for efficacy. At 8 weeks, 12 out of 14 (86%) patients who received terbinafine were mycologically negative (microscopy and culture) compared to one out of 14 (7%) patients on placebo ( P <0.001, Fishers exact test, one‐sided). At the end of the study 71% of patients in the terbinafine group were judged to have received effective therapy compared to 0% in the placebo group ( P <0.001), Terbinafine was well tolerated, and more side‐effects were seen in the placebo group.